Welcome to our dedicated page for Akebia Therapeut news (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeut stock.
Akebia Therapeutics, Inc. develops and commercializes therapeutics for people impacted by kidney disease. Company news commonly covers Vafseo® (vadadustat), an oral HIF-PH inhibitor indicated for anemia due to chronic kidney disease in adults receiving dialysis, and Auryxia® (ferric citrate), a U.S.-marketed therapy for chronic kidney disease-related conditions.
Recurring updates also address product revenue, dialysis-market access, clinical data publications, and kidney disease pipeline programs, including praliciguat in focal segmental glomerulosclerosis, AKB-097 in rare kidney diseases, and AKB-9090 for cardiac surgery-associated acute kidney injury. Akebia also reports Nasdaq inducement grants, board changes, investor presentations, and quarterly financial results.
Akebia Therapeutics (Nasdaq: AKBA) announced that vadadustat efficacy and safety data will be showcased at the ASN Kidney Week 2021 from November 4-7, 2021. Vadadustat, an oral HIF-PH inhibitor, is under FDA review with a PDUFA date of March 29, 2022. The presentation includes multiple abstracts highlighting vadadustat's potential in treating anemia due to chronic kidney disease. Additionally, Akebia will present data on Auryxia, exploring its effectiveness in preventing renal failure in CKD patients.
Akebia Therapeutics (Nasdaq: AKBA) granted stock options to 17 newly-hired employees on September 30, 2021. The options, totaling 180,000 shares, have an exercise price of $2.88 per share, equal to the stock's closing price on that date. Each option vests over four years, beginning with 25% on the first anniversary of the grant, and is subject to continued employment. This grant complies with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new talent in the biopharmaceutical sector focused on kidney disease.
On September 1, 2021, Akebia Therapeutics (Nasdaq: AKBA) announced the granting of stock options to nine new employees, totaling 89,000 shares. The options, with an exercise price of $2.94 per share, align with Nasdaq Listing Rule 5635(c)(4) and will vest over four years. 25% will vest on the first anniversary, with the remainder vesting quarterly, contingent on continued service. This strategic move is aimed at incentivizing new hires in the biopharmaceutical sector focused on kidney disease.
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced a series of investor conference participations. CEO John P. Butler and CFO David A. Spellman will partake in three significant conferences this September, including the Morgan Stanley Global Healthcare Conference on September 9, H.C. Wainwright Global Investment Conference on September 13, and Cantor Fitzgerald Global Healthcare Conference on September 27. These events aim to update investors about Akebia's progress in developing therapeutics for kidney disease. Live webcasts of these events will be available on the company's investor relations website.
Akebia Therapeutics (AKBA) reported a net loss of $83.0 million for Q2 2021, an improvement from a loss of $175.8 million in Q2 2020. Total revenue decreased to $52.9 million from $90.1 million year-over-year, primarily due to lower collaboration revenue, which fell to $20.0 million from $59.4 million. Net product revenue for Auryxia rose to $33.0 million, a 7.4% increase. Akebia announced FDA acceptance of the vadadustat NDA with a PDUFA date of March 29, 2022, indicating potential market opportunities in treating anemia due to chronic kidney disease.
Akebia Therapeutics granted stock options to 14 newly-hired employees, totaling 95,000 shares at an exercise price of $2.47 per share, equivalent to the stock’s closing price on the grant date, July 30, 2021. The stock options will vest over four years, with 25% vesting after the first year and the remainder quarterly, contingent upon continued employment. This grant complies with Nasdaq Listing Rule 5635(c)(4), reflecting Akebia's commitment to attracting talent in the biopharmaceutical sector focusing on kidney disease treatment.
Akebia Therapeutics, Inc. (Nasdaq: AKBA) has announced that it will release its financial results for the second quarter ended June 30, 2021, on August 5, 2021, before markets open. The company will also host a conference call at 9:00 a.m. ET on the same day to discuss the results and recent business developments. Interested parties can listen live by calling (877) 458-0977 domestically or (484) 653-6724 internationally. A replay will be available after the call until August 11, 2021.
Akebia Therapeutics (Nasdaq: AKBA) announced on July 1, 2021, that it granted stock options to 25 new employees, totaling 210,000 shares. These options, priced at $3.79 per share, are in accordance with Nasdaq Listing Rule 5635(c)(4). The options vest over four years, with 25% unlocking after the first anniversary and the remainder vesting quarterly, contingent upon the employees' continued service. Akebia is dedicated to improving the lives of individuals affected by kidney disease.
Akebia Therapeutics (Nasdaq: AKBA) announced upcoming presentations of data from its Phase 3 program for vadadustat at the ERA-EDTA Virtual Congress 2021 from June 5-8, 2021. The abstracts are available online in Nephrology Dialysis Transplantation. Key presentations will focus on the hematologic efficacy of vadadustat for anemia in both dialysis-dependent patients and those with non-dialysis-dependent chronic kidney disease. Vadadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, is approved in Japan but not yet in the U.S.
On June 2, 2021, Akebia Therapeutics (Nasdaq: AKBA) announced the granting of stock options to 15 new employees totaling 121,000 shares. The options were issued as inducements for employment and have an exercise price of $3.51, equivalent to the stock's closing price on the grant date. Vesting occurs over four years, with 25% vesting after one year and the remainder quarterly, contingent on continued employment. This grant complies with Nasdaq Listing Rule 5635(c)(4).